A5009091754- Acute Myeloid Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Chronic Lymphocytic Leukemia Research
- Acute Lymphoblastic Leukemia research
- Neutropenia and Cancer Infections
- Multiple Myeloma Research and Treatments
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Histone Deacetylase Inhibitors Research
- Lymphoma Diagnosis and Treatment
- Retinoids in leukemia and cellular processes
- Palliative Care and End-of-Life Issues
- Hematopoietic Stem Cell Transplantation
- Childhood Cancer Survivors' Quality of Life
- Cancer Treatment and Pharmacology
- HIV/AIDS drug development and treatment
- Head and Neck Cancer Studies
- Protein Degradation and Inhibitors
- Hematological disorders and diagnostics
- Monoclonal and Polyclonal Antibodies Research
- Cancer-related Molecular Pathways
- Immunodeficiency and Autoimmune Disorders
- Cancer Genomics and Diagnostics
- Salivary Gland Tumors Diagnosis and Treatment
- Eosinophilic Disorders and Syndromes
- Hemoglobinopathies and Related Disorders
Massachusetts General Hospital
2016-2025
Leukemia Research Foundation
2025
Harvard University
2013-2023
American University of Beirut
2016
Dana-Farber Cancer Institute
1999-2015
Wake Forest University
1997-2012
University of North Carolina at Chapel Hill
2012
Mass General Brigham
2012
Duke University Hospital
2012
Boston University
2004
On the basis of data suggesting that adolescents and young adult patients with acute lymphoblastic leukemia (ALL) have improved outcomes when treated on pediatric protocols, we assessed feasibility treating aged 18–50 years ALL DFCI Pediatric Consortium regimen utilizing a 30-week course pharmacokinetically dose-adjusted E. coli L-asparaginase during consolidation. Between 2002 2008, 92 eligible were enrolled at 13 participating centers. Seventy-eight (85%) achieved complete remission (CR)...
Abstract Purpose: Previous evaluation of HER2 overexpression in salivary gland cancers indicated an incidence varying between 7 and 56%, with no clear difference among three histologically different subtypes. As part a Phase II trial trastuzumab for treatment incurable cancer, we screened 137 tumors expression. Experimental Design: Unstained sections paraffin-embedded tumor samples were stained p185/HER2 receptor antibody. Tumors moderate (2+) to strong (3+) complete membrane staining at...
BACKGROUND Health care utilization in older adults (age ≥60 years) with acute myeloid leukemia (AML) has not been well studied. METHODS We conducted a retrospective analysis of 330 consecutive patients who were diagnosed AML between May 1, 2005 and December 23, 2011, at 2 hospitals Boston to examine their health end‐of‐life care. Using multivariable logistic linear regression models adjusting for covariates, we also compared received intensive induction chemotherapy (n = 197; cytarabine/...
Chronic lymphocytic leukemia (CLL) cells treated with dasatinib in vitro undergo apoptosis via inhibition of Lyn kinase. Thus, this study we tested the activity patients relapsed CLL.
Purpose The purpose of this study was to determine remission induction frequency when bortezomib combined with daunorubicin and cytarabine in previously untreated older adults acute myeloid leukemia (AML) safety combination consolidation chemotherapy consisting intermediate-dose (Int-DAC). Patients Methods Ninety-five (age 60 75 years; median, 67 years) AML (including therapy-related previous myelodysplastic syndrome) received 1.3 mg/m 2 intravenously (IV) on days 1, 4, 8, 11 1 through 3 100...
Abstract Purpose: Isocitrate dehydrogenase 1 (IDH1) mutations occur in 5% to 10% of patients with acute myeloid leukemia (AML). Ivosidenib is an IDH1 inhibitor, approved for use IDH1-mutated AML. Patients and Methods: We conducted a multicenter, phase I trial maintenance ivosidenib following allogeneic hematopoietic cell transplantation (HCT) was initiated between days 30 90 HCT continued up 12 28-day cycles. The first dose level 500 mg daily, reduction 250 if needed, 3 × de-escalation...
The authors report the results of a prospective study patients with malignant neuroendocrine tumors sinonasal tract who received multimodality treatment incorporating high-dose proton-photon radiotherapy.Nineteen olfactory neuroblastoma (ONB) or carcinoma (NEC) were treated between 1992 and 1998 on study. Four had Kadish Stage B disease, 15 C disease. median patient age was 44 years. Patients chemotherapy 2 courses cisplatin etoposide followed by radiotherapy to 69.2 cobalt-Gray equivalents...
Purified muscle actin and mixtures of actin-binding protein were examined in the transmission electron microscope after fixation, critical point drying, rotary shadowing. The three-dimensional structure assemblies was analyzed by a computer-assisted graphic analysis applicable to generalized filament networks. This yielded information concerning frequency intersections, length between these angle at which filaments branch concentration within defined volume. 1 mg/ml assembled into uniform...
Abstract Purpose: Proteasome inhibition results in cytotoxicity to the leukemia stem cell vitro. We conducted this phase I study determine if proteasome inhibitor bortezomib could be safely added induction chemotherapy patients with acute myelogenous (AML). Experimental Design: Bortezomib was given on days 1, 4, 8, and 11 at doses of 0.7, 1.0, 1.3, or 1.5 mg/m2 idarubicin 12 1 3 cytarabine 100 mg/m2/day 7. Results: A total 31 were enrolled. The median age 62 years, 16 male. Nine had relapsed...
Seventy patients with squamous-cell carcinoma of the head and neck were treated a 24-hour infusion cisplatin, followed by 5-day continuous 5-fluorouracil (5-FU). Among 31 without prior treatment, stage III (six patients) IV (25 patients), there seven complete responses (CRs) 19 partial (PRs) for an overall response rate 84%. In group 30 recurrent disease after surgery and/or radiotherapy, five CRs ten PRs (total 50%). nine who failed chemotherapy, two one PR. Performance status had minor...
Isolated myeloid sarcoma (MS) is a rare extramedullary presentation of acute leukemia (AML). Little known about MS outcomes due to its rarity. A population-based analysis using the Survival, Epidemiology, and End Results (SEER) database was performed. We identified 345 patients, aged 15 or older, diagnosed with isolated between 1973 2010. Overall survival (OS) calculated compared non-MS AML log-rank test. Survival also evaluated based upon primary site disease presentation. The 3-year rate...
Mutations in isocitrate dehydrogenase 1 and 2 (IDH1/2) have been discovered several cancer types cause the neurometabolic syndrome D2-hydroxyglutaric aciduria (D2HGA). The mutant enzymes exhibit neomorphic activity resulting production of acid (D-2HG). To study pathophysiological consequences accumulation D-2HG, we generated transgenic mice with conditionally activated IDH2 R140Q R172K alleles. Global induction expression adults resulted dilated cardiomyopathy, white matter abnormalities...
Acute myeloid leukemia (AML) is more common and lethal among patients over the age of 60. Increased body mass index (BMI) has been associated with a higher incidence various malignancies, including AML. We sought to determine whether patient BMI at time AML diagnosis related overall survival (OS) elderly patients. identified 97 diagnosed after 60 treated cytarabine‐based induction chemotherapy. The median was 68 years (range 60–87); 52% were male, our study population predominantly white...
Abstract Background Older patients (≥60 years) with acute myeloid leukemia (AML) face difficult decisions regarding treatment “intensive” chemotherapy that carries significant toxicity for a small chance of cure versus “nonintensive” to control the disease, but fewer side effects. However, studies how these understand risks and benefits such treatments are lacking. Methods We conducted longitudinal study older newly diagnosed AML assessing patients’ (n = 100) oncologists’ 11) perceptions...
PURPOSE: To evaluate the toxicity and efficacy of a 4-day regimen docetaxel, cisplatin, fluorouracil, leucovorin (TPFL4) in patients with locoregionally advanced squamous cell carcinoma head neck (SCCHN). PATIENTS AND METHODS: Thirty previously untreated stage III or IV SCCHN Eastern Cooperative Oncology Group functional status 2 less were treated TPFL4. Postchemotherapy support included prophylactic growth factors antibiotics. Patients who achieved complete response (CR) partial (PR) to...
To study the efficacy of a newly designed treatment strategy for esthesioneuroblastoma and neuroendocrine carcinoma paranasal sinuses.Nonrandomized prospective case series in tertiary referral center.Nine consecutive patients with diagnosed or sinuses from June 1992 to October 1995 underwent this protocol.After histological diagnosis detailed imaging, 2 cycles cisplatin etoposide chemotherapy were instituted. Chemotherapy responders treated combined photon stereotaxic fractionated proton...
One hundred twenty-nine patients undergoing total hip replacement were treated with aspirin at a level of either 300 mg four times day (1.2 g/day) or 900 (3.6 g/day). Baseline bleeding before treatment averaged 4.18 +/- 1.44 minutes. Two hours after and aspirin, the 5.83 1.88 5.72 1.57 minutes, respectively. After three to five days therapy 1.2 g/day 3.6 g/day, 6.27 2.27 6.43 2.11 The for all aspirin-treated groups longer than baseline times. No paradoxical shortening time was noted...